Lasting effects of chronic fluoxetine treatment on the late developing rat brain: Age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI

NeuroImage

Volumn 59, Issue 1, 2012, Pages 218-226

  Klomp, A ^a   Tremoleda, J L ^b   Wylezinska, M ^b   Nederveen, A J ^a   Feenstra, M ^c   Gsell, W ^b   Reneman, L ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

5 HT system; Developing brain; Juvenile drug exposure; phMRI; SSRI

Indexed keywords

FLUOXETINE; NEUROTRANSMITTER; SEROTONIN;

ADOLESCENT; ADULTHOOD; AGE DISTRIBUTION; ANIMAL EXPERIMENT; ARTICLE; BRAIN DEVELOPMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; JUVENILE; LONG TERM CARE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERINATAL PERIOD; PHARMACOLOGICAL MRI; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SUBCORTEX;

AGE FACTORS; ANIMALS; BRAIN; FLUOXETINE; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 80054106206     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.07.082     Document Type: Article

References (72)

1. Abramoff M.D., Magelhaes P.J., Ram S.J. Image Processing with ImageJ. 11 ed 2004, 36-42.
2. Alwan S., Friedman J.M. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009, 23:493-509.
3. Andersen S.L. Trajectories of brain development: point of vulnerability or window of opportunity?. Neurosci. Biobehav. Rev. 2003, 27:3-18.
4. Andersen S.L. Stimulants and the developing brain. Trends Pharmacol. Sci. 2005, 26:237-243.
5. Andersen S.L., Navalta C.P. Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int. J. Dev. Neurosci. 2004, 22:423-440.
6. Anderson I.M., McKie S., Elliott R., Williams S.R., Deakin J.F. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology 2008, 55:1029-1037.
7. Aznavour N., Rbah L., Riad M., Reilhac A., Costes N., Descarries L., Zimmer L. A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment. NeuroImage 2006, 33:834-842.
8. Bastos E.F., Marcelino J.L., Amaral A.R., Serfaty C.A. Fluoxetine-induced plasticity in the rodent visual system. Brain Res. 1999, 824:28-35.
9. Benmansour S., Cecchi M., Morilak D.A., Gerhardt G.A., Javors M.A., Gould G.G., Frazer A. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J. Neurosci. 1999, 19:10494-10501.
10. Blakemore S.J. The social brain in adolescence. Nat. Rev. Neurosci. 2008, 9:267-277.
11. Blier P., de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999, 21:91S-98S.
12. Borue X., Chen J., Condron B.G. Developmental effects of SSRIs: lessons learned from animal studies. Int. J. Dev. Neurosci. 2007, 25:341-347.
13. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., Ren L., Brent D.A. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297:1683-1696.
14. Caccia S., Cappi M., Fracasso C., Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 1990, 100:509-514.
15. Casey B.J., Jones R.M., Hare T.A. The adolescent brain. Ann. N. Y. Acad. Sci. 2008, 1124:111-126.
16. Cipriani A., Geddes J.R., Furukawa T.A., Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can. J. Psychiatry 2007, 52:553-562.
17. Cohen Z., Bonvento G., Lacombe P., Hamel E. Serotonin in the regulation of brain microcirculation. Prog. Neurobiol. 1996, 50:335-362.
18. Crews F., He J., Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol. Biochem. Behav. 2007, 86:189-199.
19. D'Amato R.J., Blue M.E., Largent B.L., Lynch D.R., Ledbetter D.J., Molliver M.E., Snyder S.H. Ontogeny of the serotonergic projection to rat neocortex: transient expression of a dense innervation to primary sensory areas. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:4322-4326.
20. Engelbregt M.J., Houdijk M.E., Popp-Snijders C., Delemarre-van de Waal H.A. The effects of intra-uterine growth retardation and postnatal undernutrition on onset of puberty in male and female rats. Pediatr. Res. 2000, 48:803-807.
21. Faure C., Mnie-Filali O., Haddjeri N. Long-term adaptive changes induced by serotonergic antidepressant drugs. Expert. Rev. Neurother. 2006, 6:235-245.
22. Gaspar P., Cases O., Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 2003, 4:1002-1012.
23. Giedd J.N. The teen brain: insights from neuroimaging. J. Adolesc. Health 2008, 42:335-343.
24. Gozzi A., Crestan V., Turrini G., Clemens M., Bifone A. Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit. Psychopharmacology (Berl) 2010, 209:37-50.
25. Gsell W., De Sadeleer C., Marchalant Y., MacKenzie E.T., Schumann P., Dauphin F. The use of cerebral blood flow as an index of neuronal activity in functional neuroimaging: experimental and pathophysiological considerations. J. Chem. Neuroanat. 2000, 20:215-224.
26. Hammad T.A., Laughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 2006, 63:332-339.
27. Hetrick S., Merry S., McKenzie J., Sindahl P., Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst. Rev. 2007, CD004851.
28. Hiemke C., Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 2000, 85:11-28.
29. Homberg J.R., Schubert D., Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci. 2010, 31:60-65.
30. Homberg J.R., Olivier J.D., Blom T., Arentsen T., van B.C., Schipper P., Korte-Bouws G., van L.G., Reneman L. Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS ONE 2011, 6:e16646.
31. Houston G.C., Papadakis N.G., Carpenter T.A., Hall L.D., Mukherjee B., James M.F., Huang C.L. Mapping of brain activation in response to pharmacological agents using fMRI in the rat. Magn. Reson. Imaging 2001, 19:905-919.
32. Hwang L.C., Chang C.J., Liu H.H., Kao H.C., Lee S.Y., Jan M.L., Chen C.C. Imaging the availability of serotonin transporter in rat brain with 123I-ADAM and small-animal SPECT. Nucl. Med. Commun. 2007, 28:615-621.
33. Iñiguez S.D., Warren B.L., Bolanos-Guzman C.A. Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats. Biol. Psychiatry 2010, 67:1057-1066.
34. Invernizzi R., Bramante M., Samanin R. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Biochem. Behav. 1996, 54:143-147.
35. LaRoche R.B., Morgan R.E. Adolescent fluoxetine exposure produces enduring, sex-specific alterations of visual discrimination and attention in rats. Neurotoxicol. Teratol. 2007, 29:96-107.
36. Leslie R.A., James M.F. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. 2000, 21:314-318.
37. Martin C., Sibson N.R. Pharmacological MRI in animal models: a useful tool for 5-HT research?. Neuropharmacology 2008, 55:1038-1047.
38. Mason S.S., Baker K.B., Davis K.W., Pogorelov V.M., Malbari M.M., Ritter R., Wray S.P., Gerhardt B., Lanthorn T.H., Savelieva K.V. Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. Eur. J. Pharmacol. 2009, 602:306-315.
39. McKie S., Del-Ben C., Elliott R., Williams S., del Vai N., Anderson I., Deakin J.F. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) 2005, 180:680-686.
40. Moll G.H., Mehnert C., Wicker M., Bock N., Rothenberger A., Ruther E., Huether G. Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res. Dev. Brain Res. 2000, 119:251-257.
41. Morrison J.L., Riggs K.W., Rurak D.W. Fluoxetine during pregnancy: impact on fetal development. Reprod. Fertil. Dev. 2005, 17:641-650.
42. Mourilhe P., Stokes P.E. Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression. Drug Saf. 1998, 18:57-82.
43. Murray M.L., Wong I.C., de Vries C.S. Treating major depression in children and adolescents: research is needed into safer and more effective drugs. BMJ 2004, 328:524-525.
44. Navailles S., Hof P.R., Schmauss C. Antidepressant drug-induced stimulation of mouse hippocampal neurogenesis is age-dependent and altered by early life stress. J. Comp. Neurol. 2008, 509:372-381.
45. Norcross M., Poonam M., Enoch A., Karlsson R.M., Brigman J., Cameron H., Harvey-White J., Holmes A. Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice. Psychopharmacology 2008, 200:413-424.
46. Norrholm S.D., Ouimet C.C. Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine proliferation in hippocampus. Brain Res. 2000, 883:205-215.
47. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 2006, 63:898-906.
48. Oh J.E., Zupan B., Gross S., Toth M. Paradoxical anxiogenic response of juvenile mice to fluoxetine. Neuropsychopharmacology 2009, 34:2197-2207.
49. Olivier J.D., Blom T., Arentsen T., Homberg J.R. The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1400-1408.
50. Paus T., Zijdenbos A., Worsley K., Collins D.L., Blumenthal J., Giedd J.N., Rapoport J.L., Evans A.C. Structural maturation of neural pathways in children and adolescents: in vivo study. Science 1999, 283:1908-1911.
51. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney.
52. Preece M.A., Taylor M.J., Raley J., Blamire A., Sharp T., Sibson N.R. Evidence that increased 5-HT release evokes region-specific effects on blood-oxygenation level-dependent functional magnetic resonance imaging responses in the rat brain. Neuroscience 2009, 159:751-759.
53. Raap D.K., Garcia F., Muma N.A., Wolf W.A., Battaglia G., Van de Kar L.D. Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/z proteins. J. Pharmacol. Exp. Ther. 1999, 288:561-567.
54. Racagni G., Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin. Neurosci. 2008, 10:385-400.
55. Scanley B.E., Kennan R.P., Gore J.C. Changes in rat cerebral blood volume due to modulation of the 5-HT1A receptor measured with susceptibility enhanced contrast MRI. Brain Res. 2001, 913:149-155.
56. Schule C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J. Neuroendocrinol. 2007, 19:213-226.
57. Schwarz A.J., Danckaert A., Reese T., Gozzi A., Paxinos G., Watson C., Merlo-Pich E.V., Bifone A. A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI. NeuroImage 2006, 32:538-550.
58. Schwarz A.J., Gozzi A., Reese T., Bifone A. In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. NeuroImage 2007, 34:1627-1636.
59. Sekar S., Verhoye M., Van A.J., Vanhoutte G., Lowe A.S., Blamire A.M., Steckler T., Van der Linden A., Shoaib M. Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 2011, 213:521-531.
60. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H., Bannister P.R., De L.M., Drobnjak I., Flitney D.E., Niazy R.K., Saunders J., Vickers J., Zhang Y., De S.N., Brady J.M., Matthews P.M. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 2004, 23(Suppl. 1):S208-S219.
61. Sowell E.R., Delis D., Stiles J., Jernigan T.L. Improved memory functioning and frontal lobe maturation between childhood and adolescence: a structural MRI study. J. Int. Neuropsychol. Soc. 2001, 7:312-322.
62. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 2000, 24:417-463.
63. Stark J.A., Davies K.E., Williams S.R., Luckman S.M. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. NeuroImage 2006, 31:1228-1237.
64. Strupp J.P. Stimulate: A GUI based fMRI Analysis Software Package. 3 ed 1996, S607.
65. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol. Rev. 2006, 58:115-134.
66. Wegerer V., Moll G.H., Bagli M., Rothenberger A., Ruther E., Huether G. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J. Child Adolesc. Psychopharmacol. 1999, 9:13-24.
67. Whitaker-Azmitia P.M., Druse M., Walker P., Lauder J.M. Serotonin as a developmental signal. Behav. Brain Res. 1996, 73:19-29.
68. Wilens T.E., Cohen L., Biederman J., Abrams A., Neft D., Faird N., Sinha V. Fluoxetine pharmacokinetics in pediatric patients. J. Clin. Psychopharmacol. 2002, 22:568-575.
69. Wohlfarth T.D., van Zwieten B.J., Lekkerkerker F.J., Gispen-de Wied C.C., Ruis J.R., Elferink A.J., Storosum J.G. Antidepressants use in children and adolescents and the risk of suicide. Eur. Neuropsychopharmacol. 2006, 16:79-83.
70. Woolrich M.W., Jbabdi S., Patenaude B., Chappell M., Makni S., Behrens T., Beckmann C., Jenkinson M., Smith S.M. Bayesian analysis of neuroimaging data in FSL. NeuroImage 2009, 45:S173-S186.
71. Worsley K.J. Statistical analysis of activation images. Functional MRI: An Introduction to Methods 2001, OUP. P. Jezzard, P.M. Matthews, S.M. Smith (Eds.).
72. Zito J.M., Safer D.J., DosReis S., Gardner J.F., Soeken K., Boles M., Lynch F. Rising prevalence of antidepressants among US youths. Pediatrics 2002, 109:721-727.